Answers are grounded in this paper and cite their sources.
The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years under an EUA is interim and will be updated as additional information becomes available. The Pfizer-BioNTech COVID-19 vaccine has high efficacy (>90%) against COVID-19 in children aged 5-11 years, and ACIP determined benefits outweigh risks for vaccination. Vaccination is important to protect children against COVID-19 and reduce community transmission of SARS-CoV-2.
No takes yet. Share an insight, caveat, or question.
Woodworth et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: